Centers for Medicare & Medicaid Services (CMS) released preliminary weighted median private payor rates for clinical diagnostic laboratory tests for the 2027 calendar year (CY). If implemented as proposed, the preliminary rates will result in significant reimbursement reductions for clinical lab providers paid under the clinical lab fee schedule (CLFS).
Organizations have a tight 30-day window following publication to review raw data, evaluate outlier exclusions, and submit public comments to CMS. Final CY 2027 rates are scheduled to be released in November 2026. Written comments should be submitted electronically to CLFS_Annual_Public_Meeting@cms.hhs.gov, and are due on October 21, 2026.
CMS’s preliminary assessment is based on the second full data collection cycle under the Protecting Access to Medicare Act of 2014 (PAMA). According to the agency, the data indicates that CMS is paying substantially more than commercial insurers for many clinical tests. Lab providers can expect an average potential rate reduction at roughly 16% across 1,171 codes. Specialized categories like Genomic Sequencing and Molecular Pathology could face drops exceeding 20%.
In a break for providers, the Consolidated Appropriations Act, 2026 mandates a statutory phase-in from 2027 through 2029, capping annual payment reductions at a maximum of 15% per year to prevent market shock.
Our Advis experts are ready and available to assist your organization through financial impact modeling, comment submissions, and navigating these new CLFS rate adjustments. Contact us online or at 708.478.7030 for further guidance.
Published September 23, 2026